163 related articles for article (PubMed ID: 32328976)
1. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies.
Gallais F; Ysebaert L; Despas F; De Barros S; Dupré L; Quillet-Mary A; Protin C; Thomas F; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacokinet; 2020 Sep; 59(9):1171-1183. PubMed ID: 32328976
[TBL] [Abstract][Full Text] [Related]
2. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment.
Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M
Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551
[TBL] [Abstract][Full Text] [Related]
3. A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib.
Karvaly GB; Vincze I; Balogh A; Köllő Z; Bödör C; Vásárhelyi B
Molecules; 2022 Jul; 27(15):. PubMed ID: 35897942
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Ibrutinib in Healthy Adults.
Al-Ghazawi M; Saleh MI; Najib O; Salem I; Najib N
Eur J Drug Metab Pharmacokinet; 2021 May; 46(3):405-413. PubMed ID: 33740218
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6.
de Jong J; Mitselos A; Jurczak W; Cordoba R; Panizo C; Wrobel T; Dlugosz-Danecka M; Jiao J; Sukbuntherng J; Ouellet D; Hellemans P
Pharmacol Res Perspect; 2020 Oct; 8(5):e00649. PubMed ID: 32945596
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
8. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Beauvais D; Goossens JF; Boyle E; Allal B; Lafont T; Chatelut E; Herbaux C; Morschhauser F; Genay S; Odou P; Danel C
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1093-1094():158-166. PubMed ID: 30029202
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib dose modifications in the management of CLL.
Hardy-Abeloos C; Pinotti R; Gabrilove J
J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
[TBL] [Abstract][Full Text] [Related]
11. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
[TBL] [Abstract][Full Text] [Related]
12. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
13. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
[TBL] [Abstract][Full Text] [Related]
14. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
15. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Mato AR; Nabhan C; Thompson MC; Lamanna N; Brander DM; Hill B; Howlett C; Skarbnik A; Cheson BD; Zent C; Pu J; Kiselev P; Goy A; Claxton D; Isaac K; Kennard KH; Timlin C; Landsburg D; Winter A; Nasta SD; Bachow SH; Schuster SJ; Dorsey C; Svoboda J; Barr P; Ujjani CS
Haematologica; 2018 May; 103(5):874-879. PubMed ID: 29419429
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.
Rood JJM; van Hoppe S; Schinkel AH; Schellens JHM; Beijnen JH; Sparidans RW
J Pharm Biomed Anal; 2016 Jan; 118():123-131. PubMed ID: 26540627
[TBL] [Abstract][Full Text] [Related]
18. Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial.
Lavezzi SM; de Jong J; Neyens M; Cramer P; Demirkan F; Fraser G; Bartlett N; Dilhuydy MS; Loscertales J; Avigdor A; Rule S; Samoilova O; Goy A; Ganguly S; Salman M; Howes A; Mahler M; De Nicolao G; Poggesi I
Pharm Res; 2019 May; 36(7):93. PubMed ID: 31044267
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
20. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
